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Sarcopenia, an age-related decline inmusclemass and function, is affecting the older populationworldwide. Sarcopenia is associated
with poor health outcomes, such as falls, disability, loss of independence, and mortality; however it is potentially treatable if
recognized and intervened early. Over the last two decades, there has been significant expansion of research in this area. Currently
there is international recognition of a need to identify the condition early for intervention and prevention of the disastrous
consequences of sarcopenia if left untreated. There are currently various screening tools proposed. As yet, there is no consensus
on the best tool. Effective interventions of sarcopenia include physical exercise and nutrition supplementation. This review paper
examined the screening tools and interventions for sarcopenia.
1. Introduction
Physiological changes to body composition with aging are
well known [1]. Muscle mass is lost at a rate of approximately
8% per decade from the age of 50 years until the age of 70
years, after which weight loss is coupled with an accelerated
loss of muscle mass, reaching a rate of 15% per decade [2].
There is now general agreement that sarcopenia includes loss
of muscle mass, strength, and function. However, ongoing
debate continues in relation to the optimal cutoff values for
diagnosing sarcopenia and, more practically, the most appro-
priate clinical tool to use for screening [3].
Sarcopenia is common and its prevalence will rise with
population aging.Theprevalence of sarcopenia is said to range
between 5% and 13% in community-dwelling older people
aged 65 years and over. This prevalence is higher in those 80
years and older (e.g., one in five) and those who reside in resi-
dential care or in hospital setting [3]. Sarcopenia is important
clinically because of the harm related to it. It has been
described that sarcopenia is an independent predictor of falls
[4], disability [5], loss of independence [5], and increased
mortality [6–8]. In one study conducted in the United States
in 2000, it was estimated that 1.5% of the total health care
expenditure was attributable to sarcopenia [9]. The authors
concluded that a 10% reduction in sarcopenia could poten-
tially save US$1.1 billion in health-related costs.
According to the operational definition by European
Working Group on Sarcopenia in Older People (EWGSOP),
the diagnosis of sarcopenia requires the presence of low
muscle mass, with either the presence of low grip strength or
low physical performance [10]. Current diagnostic methods
for sarcopenia include measuring muscle mass using either
dual-energy X-ray absorptiometry (DXA) or bioelectrical
impedance analysis (BIA) [3]. However, these tools are not
practical for clinical practice because they are costly and
require burdensome trips to a health facility. Other methods
such as computed tomography (CT) or magnetic resonance
imaging (MRI), whilst accurate, are not practical and expen-
sive and expose patient to radiation. Therefore, using a diag-
nostic approach to detect presence of sarcopenia will be time
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consuming and expensive and requires highly specialized
equipment.
Sarcopenia is very often not noticeable in earlier phases
but becomes more apparent once a critical event such as a fall
has occurred or disability has set in [11]. While it is possible
to preserve skeletal muscle mass in older age, it is extremely
challenging to regain substantial quantities once the loss has
occurred. Therefore, a screening strategy to a larger popu-
lation in the community that allows for early detection is
important. An ideal screening test that is clinically useful
should be safe, have a reasonable cutoff level defined, be
cost-effective and is both valid and reliable, easily performed
in clinical setting that does not require further training,
with reasonable accurate sensitivity and specificity [12]. It is
currently a prevalent view that screening approach is to target
those who are screen “positive” or “high risk” of sarcopenia
with a multidisciplinary intervention, so that prescriptive
intervention by optimizing nutrition and exercise could
reduce the rate of muscle loss, thus preventing sarcopenia.
This review aims to examine the literature on screening
tools and interventions for sarcopenia.With this information,
clinicianswill hopefully be better able tomake an earlier diag-
nosis and intervene to prevent a decline in physical health.
2. Screening Method for Sarcopenia
Despite increasing research into sarcopenia, there appears to
be a dearth of practical and implementable clinical screening
tool to support the early identification of sarcopenia in pri-
mary care. In general, current screening methods have taken
the approach of either developing a screening questionnaire,
a diagnostic grid, or prediction equations. Screening test is
defined by sensitivity, specificity, positive predictive value
(PPV), and negative predictive value (NPV). As a general
rule, a “rule-out” screening test is one that has high sensitivity
and high NPV, whilst a “rule-in” screening test would have
high specificity and high PPV [13]. Current screening meth-
ods are mostly “rule-out” tests identifying those not at-risk
of sarcopenia in the community. It is currently unknown if
any one tool is superior to the others because no head-to-
head comparison study has been performed to evaluate these
different screening tools for sarcopenia. Table 1 summarises
all the screening tools currently available.
In 2010, the first screening method for sarcopenia was
described by the EWGSOP and a two-step algorithm using
gait speed assessment and handgrip strength was recom-
mended [10]. Patients with a gait speed cutoff of ≤0.8m/s
should have their muscle mass measured to confirm presence
of sarcopenia. On the other hand, those with gait speed of
>0.8m/s undergo measurement of their handgrip strength.
Those with low handgrip strength will then be recommended
to have muscle mass tested.The gait speed cutoff was derived
from the study by Abellan van Kan et al. which found that
adverse outcomes were associated with cutoff <0.8m/s [19].
This algorithm was intended as a rule-out test. However no
derivation or validation study has been reported on the devel-
opment of this two-step screening algorithm. In one study of
3260 community-dwelling older people from Brazil, Mexico,
and Spain, 83.4% of the total participants were suspected to
have sarcopenia either by gait speed or by handgrip strength
below the cutoff as suggested above [14]. Therefore this
algorithm is of limited clinical utility in screening older adults
for sarcopenia due to the high proportion of subjects selected
to further undergo muscle mass assessment. However, this
study did not establish the proportion of positively screened
subjects who are actually sarcopenic. These findings indicate
that the EWGSOP proposed cutoff values for gait speed and
handgrip strength may not be widely usable across different
populations.
Working on the principles that clinicians prefer sim-
ple questionnaires, Malmstrom and Morley developed the
SARC-F where the following five domains were assessed:
strength, ambulation (walking independence), rising from a
chair, stair climbing, and history of falls [20]. The total score
was 10 points with each domain scoring two. A score of 4
or more indicates a risk of sarcopenia and has been demon-
strated to be associated with poor outcomes in older adults
[20] (Table 1). This tool is intended to identify older peo-
ple who require diagnostic evaluation for sarcopenia. Woo
and colleagues have demonstrated the comparability of the
SARC-F to three major consensus definitions for sarcope-
nia (American, European, and Asian) in 4000 community-
dwelling older people in Hong Kong [21]. This questionnaire
was found to be a suitable tool to exclude older peoplewithout
sarcopenia, hence avoiding unnecessary and inconvenient
investigations for those not at-risk [21]. Furthermore, Cao et
al. showed that a score of SARC-F ≥ 4 is associated with poor
physical function and hospitalization of falls in the previous
2 years adds to the strength and usefulness of this tool [22].
The strength of this screening tool is that the questions are
very simple and it does not require complex measurements
of strength or gait speed (Table 2). In addition, this tool has
been linked to predicting clinical outcome and therefore has
clinical relevance when the result screen is positive using this
screening tool. However, the ability of this screening tool to
monitor for improvement or deterioration is not known and,
also, this tool has mainly been investigated in the community
setting. Its efficacy in hospitals or residential aged care is not
known.
Goodman et al. on the other handhaveproposed a screen-
ing grid for low muscle mass by age and body mass index
(BMI) [15]. The grid was derived from the National Health
and Nutrition Examination Surveys (NHANES) 1999–2004
data where appendicular skeletal mass (ASM) was calculated
from DXA measurements. The older person was classified as
having low muscle mass if their skeletal muscle index (SMI)
[ASM/height2] was one standard deviation (SD) below the
mean SMI of young adults (20–40 years old). It should be
noted that this cutoff is different to the less than two SD SMI
recommended by EWSGOP to diagnose low muscle mass.
This grid has been validated in a cohort of patients aged
65 years and above who attended the University of Utah
Health Care System. However, this screening grid has not
been externally validated or evaluated in a wider population.
Ishii et al. developed a simple screening test to identify
older adults at high risk for sarcopenia based on the EWGSOP
criteria of ASM, grip strength, and usual gait speed [16].They
found that the probability of sarcopenia could be estimated
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Table 2: Strengths and weaknesses of sarcopenia screening tools.
Strengths/advantages Limitations/disadvantages
EWGSOP
algorithm [10] Simple two-step algorithm
No validation studies evaluated this tool
Sensitivity, specificity, PPV, and NPV of this tool
are unknown
Limited clinical utility in screening older adults
for sarcopenia due to the high proportion of
subjects selected to further undergo muscle
assessment
Goodman et al.
[15] Uses two simple variable
Age range limited to 65–85 years
Adults with morbid obesity and significant
disability were excluded from the derivation study
Screening for only probability of low muscle mass
Ishii et al. [16] Simple tool requiring three variables
External validity is unknown
Calf circumference is not currently a routine
measurement in clinical practice and therefore
may require training to measure this accurately
SARC-F
questionnaire [20]
Uses 5 questions without requiring measurements
involving cutoff values
They have comparable specificity and predictive
power for adverse outcomes when validated
against criteria requiring measurements
developed by consensus panels (American,
European, and Asian).
Rapid screening and cost-effective
Low sensitivity may miss out people who are
sarcopenic but classified as “not sarcopenic”
according to SARC-F




Good discriminatory tool as a “rule-out”
screening test
Variables are already a routine clinical practice
such as measurement of weight, height, and
gender
Can be used as screening tool in primary care
setting
Not yet validated in care facility residents or
hospital inpatients
Not yet validated in non-Caucasian population.
EWGSOP: European Working Group on Sarcopenia in Older People; NPV: negative predictive value; SARC-F: slowness, assistance with walking, rising from
chair, climbing stairs, and falls questionnaire; PE: prediction equation; PPV: positive predictive value.
using a score chart, which includes three variables: age, grip
strength, and calf circumference (Table 1). The sensitivity,
specificity, and positive and negative predictive values of this
tool are shown in Table 1 but essentially this tool worked best
to rule-out those at-risk of sarcopenia. This tool was devel-
oped in a Japanese population and has not undergone exter-
nal validation or been tested with other ethnic populations
(Table 2).
Yu and colleagues inAustralia have developed a screening
method incorporating the use of an anthropometric predic-
tion equation for appendicular skeletal musclemass (ASMPE)
[17, 18]. With this study, the researchers demonstrated that
when the anthropometric PE was combined with a measure
of muscle function such as grip strength, that screening
method was able to “rule-out” those not at-risk of sarcopenia
(Table 1). There is a further need to research this method
with gait speed. There is also the opportunity to improve the
accuracy of thismethod by improving the performance of the
ASMPE.
Other anthropometric measurements such as calf cir-
cumference have been proposed as a screening tool for sar-
copenia. Although calf circumference correlated with ASM
in 1458 community-dwelling French women aged above 70
years, it was unable to predict sarcopenia defined by the ASM
estimated with DXA [23]. Despite its low cost and ability to
predict physical function, calf circumference is not a good
screening tool for sarcopenia. Furthermore, this measure-
ment has also not been studied in male participants [23].
3. Interventions
It is better to prevent progressive loss of skeletal muscle mass,
strength, and function rather than try to restore it at older age.
Preventive strategies go along with treatment interventions
and should be initiated as early as possible before the loss
of skeletal muscle mass, strength, and function will occur.
Exercise interventions and nutritional approach play a sig-
nificant role in the management of sarcopenia. The literature
indicates that exercise interventions have themost significant
improvement on sarcopenia [24]. Other evidence goes fur-
ther to suggest that the combination of exercise and nutrition
is the key intervention to prevent, treat, and slow down the
progress of sarcopenia [25]. Pharmaceutical agents are still
under investigation with no clear evidence of benefit yet.
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4. Physical Activity and Exercise Intervention
Physical activity is defined as any movement produced by
the contraction of skeletal muscles that increases energy
expenditure [26]. The term “physical activity” comprises all
kinds of activities (e.g., daily activities) while exercise is char-
acterized as a planned, structured, and repetitive movement
to improve or maintain components of physical function
and fitness [27]. Therefore, exercise is a form of physical
activity with a specific purpose and is typically described by
type, intensity, frequency, and duration. Exercise increases
muscle strength and muscle mass and improves physical
performance. Evidence shows that progressive resistance and
aerobic exercises are most beneficial for the prevention and
treatment of sarcopenia [28].
Muscular strength is the ability to generatemaximal force
by a single muscle or a muscle group but this decreases with
aging [10].Muscular hypertrophy is the enhancement ofmus-
cle size through mechanical, metabolic, and hormonal pro-
cesses [29]. Muscular power is a product of force and speed
and it is a significant predictor of performing activities of
daily living [30]. Muscular power declines more steeply with
age compared to muscular strength but appears to be amena-
ble to intervention in older people with sarcopenia [31].
4.1. Progressive Resistance Exercise. Resistance exercise com-
prises dynamic and static contractions against an external
resistance with a progressive increase over time [32]. Resis-
tant training can be executed on resistance machines in the
gymnasium, by lifting weights, stretching bands, or using
the individual’s body weight. Resistant training improves
muscle strength and mass by improving protein synthesis in
skeletal muscle cells [24]. This leads to muscle hypertrophy
and increasesmuscle power [30]. Resistance training is a safe,
feasible, and effective intervention for older people and it is
strongly recommended for people with sarcopenia [11, 33].
In older people, resistance exercise should be performed
on two or three nonconsecutive days per week with at least
one set of 8–12 repetitions (experts recommend 10–15) of the
major muscle groups [34]. The load can be increased by 2–
10%when two sets can be performed over the desired number
on two consecutive training sessions [33].
A 2009 Cochrane review of 121 trials with 6,700 partic-
ipants assessed the effects of progressive resistance training
on physical function of older people [35]. In most trials,
resistance exercise was performed 2-3 times a week at a high
intensity. Resistance exercise had a large positive effect on
muscle strength and a small but significant improvement in
physical ability. There was a modest improvement in gait
speed but a larger effect on getting up from a chair.The review
concluded that resistance exercise is an effective intervention
for improving strength and physical functioning in older
people. However adverse events were not adequately reported
in many studies and translation of these findings into clinical
practice has to be approached cautiously.
4.2. Aerobic Exercise. Aerobic exercise is a form of structured
physical activity using oxygen to meet the energy demands
during exercise [36]. Examples of aerobic exercise are swim-
ming, brisk walking, cycling, jogging, dancing or water aer-
obics. Aerobic exercise improves metabolic control, reduces
oxidative stress, and optimizes exercise capacity [33]. It has
also beneficial impact on sarcopenia by improving skeletal
muscle insulin sensitivity; stimulating skeletal muscle hyper-
trophy; and increasing skeletal muscle mass [24, 37]. How-
ever, it does not produce the samemagnitude of improvement
in muscle mass and strength as resistance exercise, but it
is still recommended for patients with sarcopenia [11, 33].
Table 3 summarises the recommendation of aerobic exercise
in sarcopenic individuals.
A recent systematic review on exercise interventions for
sarcopenia determined that aerobic and resistance exercise
can improve muscle strength and physical function although
it seems not consistently to increase muscle mass [28]. The
presented recommendations illustrate a first step in the stan-
dardization of exercise interventions for sarcopenic people.
However, further research is needed to determine optimal
and significant exercise conditions for older sarcopenic peo-
ple.
5. Nutritional Interventions
5.1. Protein Supplements. Nutrition also plays an important
role in preventing and reversing sarcopenia. Daily muscle
protein turnover is regulated in large part by nutrition, espe-
cially dietary protein [41]. Increasing age is associated with
reduced appetite and early satiety resulting in many older
people failing to meet the recommended daily dietary allow-
ance (RDA) for protein which has important implications for
skeletalmuscles [11].The current RDA inAustralia for protein
in an adult is 0.75 g/kg/day [42]. However, new evidence has
shown that older adults will require higher dietary protein
(up to 1.2 g/kg/day) to counteract age-related changes in
protein metabolism and higher catabolic state associated
with chronic or acute diseases [38]. Table 3 summarises the
amount, type, and timing of protein ingestion. The table also
included the adjusted amount of dietary protein intake in the
setting of renal failure.
5.2. Essential AminoAcid Supplements. Branchedchain amino
acids (BCAA), such as leucine, at daily amount of either 2.5 g
or 2.8 g in combination with resistance exercise may affect
muscle protein synthesis, muscle recovery following illness,
and muscle mass (Table 3) [38]. BCAA has shown beneficial
effects on sarcopenic patients who are severely ill [43]. How-
ever, the number of studies using this supplement in older
people is still limited andnot all have shownbeneficial results.
5.3. Beta-Hydroxy-Beta-Methylbutyrate (HMB). HMB used
alone or with combination of resistance exercise or lysine
and arginine has shown some effects on improved muscle
strength and physical performance in some studies (Table 3)
[39, 40]. However, these studies were limited by small sample
size.
5.4. Vitamin D. Low serum vitamin D levels (<50 nmol/L)
are associated with reduced muscle strength and frailty [44].
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Table 3: Exercise and nutritional interventions for sarcopenia.
Exercise [33]
Type of training Frequency Intensity Duration/set
Aerobic exercise
Minimum 5 days/week for
moderate intensity
or
3 days/week for vigorous
intensity
Moderate intensity at
5-6 on a 10-point scale




intensity activity in bouts of
at least 10min each
continuous vigorous
activity for at least
20min/day
Resistance exercise
(for major muscle groups
using free weights and
machines)
At least 2 days/week Slow-to-moderate velocity60–80% of 1 RM
8–10 exercises




(to practice only after the
resistance training)
Two days a week
High repetition velocity
Light-to-moderate loading




Intervention Evidence or recommendation
Amount of protein Type of protein Timing
Protein supplement
At least 1.0–1.2 g/kg/day in
people aged 65 years and
above
GFR 30–60—0.8 g/kg/day
GFR <30—between 0.6 and
0.8 g/kg/day
“Fast” proteins are thought
to be more beneficial
compared to “slow”
proteins but lacks robust
evidence.
Even distribution of protein
intake in main meals
through the day
Vitamin D Replace depleted serum vitamin D level and maintain adequate intake at 700 to1000 IU/day of cholecalciferol
∗Essential amino acid
supplementation
Daily leucine 2.5 g or 2.8 g with combination of resistance exercise (benefits only




HMB alone, or with combination of resistance exercise or arginine and lysine
(evidence not consistently positive and only shown in a small number of studies)
GFR: glomerular filtration rate, mL/min/1.73m2. ∗Not currently incorporated into mainstream of treatment.
Hence, it is paramount that a depleted serum vitamin D level
be replaced and adequate intake is maintained according to
current recommendations (i.e., 700 to 1000 IU/day of chole-
calciferol) in all older people with sarcopenia [45]. Cholecal-
ciferol in doses of 800 IU/day has been shown to decrease the
risk of falls and this reduction is partly related to improved
muscle strength [46].
6. Combination of Exercise and Nutrition
Regularly performed exercise, including resistance training,
combined with an adequate nutritional intake seems to be
the best way to prevent and treat sarcopenia [25]. There is
evidence that resistance exercise combined with protein sup-
plementation leads to greater muscle mass gain compared
to resistance exercise or protein supplementation alone [47].
Other evidence suggests that the combination of exercise and
amino acid supplementations can be effective in enhancing
muscle strength, muscle mass, and walking speed in sarcope-
nia [48]. Also the dose of protein supplementation seems
to play a significant role in the enhancement of resistance
exercise and muscle protein synthesis. Evidence shows that
resistance exercise increases muscle protein synthesis in the
elderly at all protein doses, but to a greater extent with higher
protein doses of 40 g [49]. Therefore, exercise and nutrition
in combination should be always considered as a significant
and important strategy in the prevention and treatment of
sarcopenic patients.
7. Pharmacological Treatment
Many pharmacological agents such as myostatin inhibitor,
testosterone, and angiotensin converting enzyme inhibitors
and ghrelin-modulating agents are being investigated to
treat sarcopenia but there is inadequate evidence to support
their use in mainstream practice [50]. A recent proof-of-
concept randomized-controlled phase 2 study has found that
a humanized monoclonal antibody LY2495655, a myostatin
inhibitor, increased lean mass and might improve functional
measures of muscle power [51]. There are other pharmaco-
logical agents such as proteasome inhibitors and cyclophilin
inhibitor, which are currently being evaluated in terms of
their effects on skeletal muscles, but studies have so far been
restricted to animal models [52, 53].
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8. Challenges in Preventing Sarcopenia
While the idea of sarcopenia prevention and early manage-
ment makes sense, the actual clinical detection and imple-
mentation of management remain a challenge, two main
areas that require further research.
Firstly, a robust screening tool for sarcopenia is needed for
clinical practice. Although anthropometric measurements
are easy to obtain in clinical practice, their ability to predict
sarcopenia is still limited. Several biological markers have
been shown to be associated with skeletal muscle mass,
strength, and function. However, these biomarkers may not
be specific to skeletal muscle and are likely to be only weakly
associated with clinically relevant outcomes [54]. For exam-
ple, a recent study has found that copper and zinc ratio is
associated with decline in physical function and development
of disability [55]. The use of biomarkers in screening for
sarcopenia requires further investigation.
Secondly, the implementation of interventions for sar-
copenia comes with several challenges and barriers in older
people. The awareness of the benefits of exercise and diet
needs to be raised among older people. A recent systematic
review confirmed that older people still believe that exercise
is unnecessary or even potentially harmful [56]. Others rec-
ognize the benefits of exercise but report a range of barriers
to participate in exercise interventions. Raising awareness
is one of the most important strategies to enhance exercise
participation among older people and to prevent sarcopenia
on a long-term scale. Evidence shows that older people would
be more active if they were advised to do so by their general
practitioner [57].
It is more challenging for older people with activity limi-
tations to engage in physical activity or exercises. In this situa-
tion, more targeted exercise plans will need to be designed.
Another barrier in older people is the financial ability to
attend exercise programs [27]. This barrier needs to be con-
sidered in planning long-term strategies to prevent and treat
people with sarcopenia. From a dietary point of view, factors
such as access to food, finances, and social isolation may all
impact on an older person’s ability to obtain optimal food
intake. Furthermore many older people have difficulties with
swallowing and loss of taste and smell which can lead to
decrease in oral intake [11].
9. Conclusion
Strategies are needed to screen for sarcopenia and identify
effective ways for preventive and therapeutic interventions.
Several tools are currently available to screen older people for
sarcopenia and further research is needed to determinewhich
is most effective for use in the general population. Exercise
and nutrition remain the cornerstone for good health and
prevention of sarcopenia. Adequate dietary protein intake is
an important measure to prevent or delay sarcopenia in the
elderly. It is currently difficult to recommend any pharmaco-
logical agents as part of routine treatment of sarcopenia until
larger long-term studies have found evidence to support their
safe and effective use.
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